Related Experiment Video
Updated: Jul 10, 2026
09:12
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Chronic microglial activation and progressive dopaminergic neurotoxicity
1Neuropharmacology Section, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, U.S.A. mblock@vcu.edu
Biochemical Society Transactions
|October 25, 2007
Summary
Chronic neuroinflammation driven by persistent microglial activation contributes to dopaminergic neuron loss in Parkinson's disease. Understanding these mechanisms is key to developing new treatments for this neurodegenerative condition.
Area of Science:
- Neuroscience
- Immunology
- Neurodegenerative Diseases
Background:
- Parkinson's disease involves progressive loss of dopaminergic neurons.
- Neuroinflammation and microglial activation are implicated in Parkinson's disease pathogenesis.
- Microglia can produce toxic factors like cytokines and reactive oxygen species (ROS).
Purpose of the Study:
- To review mechanisms of chronic neuroinflammation in Parkinson's disease.
- To explain the link between microglial activation and dopaminergic neuron damage.
- To explore the relationship between neuroinflammation and neurodegeneration.
Main Methods:
- Literature review of proposed mechanisms.
- Analysis of microglial activation pathways.
- Examination of the interplay between glial cells and neurons.
Main Results:
- Microglia activation can persist long after initial stimuli.
- Dying neurons and glial signals may sustain chronic microglial activation.
- Chronic inflammation exacerbates dopaminergic neuron damage.
Conclusions:
- Persistent microglial activation is a key driver of neurodegeneration in Parkinson's disease.
- Understanding these inflammatory mechanisms is crucial for therapeutic development.
- Targeting microglial pathways may offer novel treatment strategies for Parkinson's disease.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...